Breaking News, Collaborations & Alliances

Optimvia, Ginkgo Bioworks to Manufacture Biosynthetic Heparin

Optimvia to leverage Ginkgo's cell and enzyme engineering platform to improve the performance of Optimvia's biosynthetic heparin manufacturing technology.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Optimvia, a biotechnology company specializing in engineering enzymes and their cofactors to synthesize complex therapeutic molecules, and Ginkgo Bioworks, the horizontal platform for cell programming, partnered to improve the manufacturing efficiency of biosynthetic heparin, an essential medicine currently produced from industrial animal agriculture. Under the partnership, Optimvia seeks to leverage Ginkgo’s cell and enzyme engineering platform, as well as its fermentation process develop...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters